Improving the consistency of ovarian stimulation: Follitropin alfa filled-by-mass

Reproductive BioMedicine Online

Volumn 12, Issue 6, 2006, Pages 663-668

  Wikland, Matts ^a   Hugues, Jean Noël ^b   Howles, Colin ^c  

^a Carlanderska Hospital   (Sweden)

^b UNIVERSITÉ PARIS 13   (France)

^c Serono Singapore Pte   (Singapore)

Author keywords

Assisted conception; Filled by mass; Ovarian stimulation; Quality control; Recombinant FSH; Urinary FSH

Indexed keywords

FOLLITROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

CLINICAL TRIAL; CONCEPTION; EMOTIONAL STRESS; EXPECTATION; EXPERIENCE; FEMALE; HOPE; HUMAN; INFERTILITY; INFERTILITY THERAPY; OVARY CYCLE; OVARY HYPERSTIMULATION; PREGNANCY; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33745047821     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61078-4     Document Type: Article

References (46)

1. Abuzeid M, Kelly E, Loumaye E et al. 2001 A new formulation of Gonal-f® (r-hFSH) filled by mass delivers more and better oocytes and embryos with a lower cumulative dose when compared with the current follitropin alfa preparation in ovarian stimulation for ART. Preliminary data. 8th Annual Scientific Meeting of the Middle East Fertility Society (MEFS), Bahrain, 7-10 November 2001, Abstract O-33.
2. Alper MM, Brinsden PR, Fischer R et al. 2002 Opinion: is your IVF programme good? Human Reproduction 17, 8-10.
3. Balasch J, Fábregues F, Peñarrubia J et al. 2004 Outcome from consecutive assisted reproduction cycles in patients treated with recombinant follitropin alfa filled-by-bioassay and those treated with recombinant follitropin alfa filled-by mass. Reproductive BioMedicine Online 8, 408-413.
4. Bassett RM, Driebergen R 2005 Continued improvements in the quality and consistency of follitropin alfa, recombinant human follicle stimulating hormone. Reproductive BioMedicine Online 10, 169-177.
5. Bertarelli Group 2003 Infertility therapy-associated multiple pregnancies (births): and ongoing epidemic. Proceedings of an Expert Meeting. Reproductive BioMedicine Online 7, 515-542.
6. Bhattacharya S, Templeton A 2004 Debate: what is the most relevant standard of success in assisted reproduction? Human Reproduction 19, 1939-1942.
7. De Neubourg D, Gerris J 2003 Single embryo transfer - state of the art. Reproductive BioMedicine Online 7, 615-622.
8. De Sutter P, Van der Elst J, Coetsier T et al. 2003 Single embryo transfer and multiple pregnancy rate reduction in IVF/ICSI: a 5 year appraisal. Reproductive BioMedicine Online 6, 464-469.
9. Donini P, Puzzuoli D, D'Alessio I et al. 1966. Purification and separation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from human postmenopausal gonadotrophin (HMG). Acta Endocrinologica 52, 169-185.
10. Donini P, Puzzuoli D, Montezemolo R 1964 Purification of gonadotropin from human menopausal urine. Acta Endocrinologica 45, 329-329.
11. Driebergern R, Baer G 2002 Quantification of follicle-stimulating hormone (follitropin alspa): is in vivo bioassay still relevant in the recombinant age? Current Medical Research Opinion 19, 41-46.
12. Flack MR, Bennet AP, Froehlich J et al. 1994 Increased biological activity due to basic isoforms in recombinant human follicle-stimulating hormone produced in a human cell line. Journal of Clinical Endocrinology and Metabolism 79, 756-760.
13. Gervais A, Hammel Y-A, Pelloux S et al. 2003 Glycosylation of human recombinant gonadotrophins: characterization and batch-to-batch consistency. Glycobiology 13, 179-189.
14. Gleicher N, Vanderlaan B, Karande V et al. 1996 Infertility treatment dropout and nuance coverage. Obstetrics and Gynecology 88, 289-293.
15. Guidice E, Crisci C, Altarocca V et al. 2001 Characterisation of a partially purified human menopausal gonadotropin preparation. Journal of Clinical Research 4, 27-33.
16. Guidice E, Crisci C, Eshkol A et al. 1994 Composition of commercial gonadotrophin preparations extracted from human postmenopausal urine: characterization of non-gonadotrophin proteins. Human Reproduction 9, 2291-2299.
17. Gurgan T, Demirol A 2004 Why and how should multiple pregnancies be prevented in assisted reproduction treatment programmes? Reproductive BioMedicine Online 9, 237-244.
18. Halman KJ, Abbey A, Andrews FM 1993 Why are couples satisfied with infertility treatment? Fertility and Sterility 59, 1046-1054.
19. Hammarberg K, Astbury J, Baker H 2001 Women's experience of IVF: a follow-study. Human Reproduction 16, 374-383.
20. Heijnen EMEW, Macklon NS, Fauser BCJM 2004 Debate: what is the most relevant standard of success in assisted reproduction? The next step to improving outcomes of IVF: consider the whole treatment. Human Reproduction 19, 1936-1938.
21. Hill AF, Collinge J 2003 Subclinical prion infection in humans and animals. British Medical Bulletin 66, 161-170.
22. Howles CM 1996 Genetic engineering of human FSH (Gonal-f). Human Reproduction Update 2, 172-191.
23. Hugues JN, Barlow DH, Rosenwaks Z et al. 2003 Improvement in consistency of response to ovarian stimulation with recombinant human follicle stimulating hormone resulting from a new method for calibrating the therapeutic preparation. Reproductive BioMedicine Online 6, 185-190.
24. Keck C, Bassett R, Ludwig M 2005 Factors influencing response to ovarian stimulation. Reproductive BioMedicine Online 11, 562-569.
25. Lass A, McVeigh E, on behalf of the UK Gonal-f FbM PMS Group 2004 Routine use of r-hFSH follitropin alfa filled-by-mass for follicular development for IVF: a large multicentre observational study in the UK. Reproductive BioMedicine Online 9, 604-610.
26. Levene MI, Wild J, Steer P et al. 1992 Higher multiple births and modern management of infertility in Britain. British Journal of Obstetrics and Gynaecology 99, 607-613.
27. Loumaye E, Dreano M, Glazka A et al. 1998 Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility. Human Reproduction Update 4, 862-881.
28. Ludwig M, Rabe T, Byhler K et al. 2004 Efficacy of recombinant human FSH in comparison to urinary hMG following a long down-regulation protocol - an analysis of 24764 ART cycles in Germany. Journal Reproduktionsmedizin und Endokrinologie 1, 284-288.
29. Lunenfeld B 2004 Historical perspectives in gonadotrophin therapy. Human Reproduction Update 10, 453-467.
30. Messinis IE, Domali E 2004 Debate: what is the most relevant standard of success in assisted reproduction? Should BESST really be the primary endpoint for assisted reproduction? Human Reproduction 19, 1933-1935.
31. Min JK, Breheny SA, MacLachlan V et al. 2004 What is the most relevant standard of success in assisted reproduction? The singleton, term gestation, live birth rate per cycle initiated: the BESST endpoint for assisted reproduction. Human Reproduction 19, 3-7.
32. Norwitz ET 1998 Multiple pregnancy: trends, past, present and future. Infertility and Reproductive Clinics of North America 9, 351-369.
33. Penzias A 2004 Improving results with assisted reproductive technologies: individualized patient-tailored strategies for ovulation induction. Reproductive BioMedicine Online 9, 43-46.
34. Schmidt L 1998 Infertile couples' assessment of infertility treatment. Acta Obstetrica Gynecologica Scandinavia 77, 649-653.
35. Seeger H, Heikenwalder M, Zeller N et al. 2005 Coincident scrapie infection and nephritis lead to urinary prion excretion. Science 14, 324-326.
36. Shaked GM, Shaked Y, Kariv-Inbal Z et al. 2001 A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. Journal of Biological Chemistry 24, 31479-31482.
37. Souter VL, Penney G, Hopton JL et al. 1998 Patient satisfaction with the management of infertility. Human Reproduction 13, 1831-1836.
38. Steelman SL, Pohley FM 1953 Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotropin. Endocrinology 543, 604-616.
39. Thurin A, Hausken J, Hillensjo T et al. 2004 Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization. New England Journal of Medicine 2, 2392-2402.
40. Tredway D, Fiszbajn G, Yeko T et al. 2002 Improvement of clinical profile with Gonal-f Filled-by-Mass in ovulation induction (preliminary results from 1st treatment cycle). VIIth FLASEF Congress, Montevideo, Uruguay, 18-21 November 2002, F54.
41. Tur R, Barri PN, Coroleu B et al. 2001 Risk factors for high order multiple implantation after ovarian stimulation with gonadotrophins: evidence from a large series of 1878 consecutive pregnancies in a single center. Human Reproduction 16, 326-332.
42. van de Weijer BH, Mulders JW, Bos ES et al. 2003 Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reproductive BioMedicine Online 7, 547-557.
43. Vail A, Gardner E 2003 Common statistical errors in the design and analysis of subfertility trials. Human Reproduction 18, 1000-1004.
44. Wennerholm UB, Bergh C 2004 Debate: what is the most relevant standard of success in assisted reproduction? Singleton live births should also include preterm births. Human Reproduction 19, 1943-1945.
45. Wikland M, Sjoblom C 2000 The application of quality systems in ART programs. Molecular Cellular Endocrinology 166, 3-7.
46. Yeko T, Pasqualini SR, Alam V et al. 2004 Cumulative ovulation and pregnancy rates according to recombinant human follicle stimulating hormone (r-hFSH) dosing: comparison of a new formulation of follitropin alfa in vials versus the standard formulation of follitropin alfa in ampoules. Fertility and Sterility 82 (Suppl. 2), S 119.